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REVIEW
Inflammation in chronic obstructive 




Chronic obstructive pulmonary disease (COPD) is characterized by lung inflammation that persists after smoking ces-
sation. This inflammation is heterogeneous but the key inflammatory cell types involved are macrophages, neutro-
phils and T cells. Other lung cells may also produce inflammatory mediators, particularly the epithelial cells. The main 
inflammatory mediators include tumor necrosis factor alpha, interleukin-1, interleukin-6, reactive oxygen species and 
proteases. COPD is also associated with systemic inflammation and there is a markedly increased risk of cardiovas-
cular disease (particularly coronary artery disease) and lung cancer in patients with COPD. There is strong associative 
evidence that the inflammatory cells/mediators in COPD are also relevant to the development of cardiovascular 
disease and lung cancer. There are a large number of potential inhibitors of inflammation in COPD that may well 
have beneficial effects for these comorbidities. This is a not well-understood area and there is a requirement for more 
definitive clinical and mechanistic studies to define the relationship between the inflammatory process of COPD and 
cardiovascular disease and lung cancer.
© 2015 King. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made.
Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterized by chronic lung inflammation that results in 
progressive and irreversible airflow obstruction with 
periodic acute episodes of worsening, exacerbations. The 
airflow obstruction arises from a combination of emphy-
sema and chronic bronchitis. It is predicted to be the 
third leading cause of death worldwide by 2020 [1], is a 
major cause of disability-adjusted life years (DALY) [2] 
and has a lifetime risk of up to 25% [3]. The inflammation 
in COPD is also systemic and this contributes to impor-
tant comorbidities.
Smoking is the primary risk factor for COPD. However 
only 20–25% of smokers develop COPD. In addition once 
the inflammatory process in COPD is established it per-
sists after smoking cessation [4, 5]. The inflammation is 
also associated with manifestations in addition to airflow 
obstruction, of which the two of the most important are 
cardiovascular disease (CVD) and lung cancer [6].
There is strong associative evidence that inflammatory 
process of COPD increases the risk of CVD and lung 
cancer but the mechanisms as to how this occurs are not 
well defined. This review will examine the relationship 
between the inflammation of COPD and CVD/lung can-
cer, and how this process could be potentially targeted 
therapeutically.
The inflammatory process of COPD
The chronic inflammatory process in COPD involves 
both innate and adaptive immunity and is most pro-
nounced in the bronchial walls of the small airways. 
The inflammatory process in COPD does have marked 
heterogeneity. It results in both emphysema with paren-
chymal involvement and chronic bronchitis, which pre-
dominantly affects the small airways. A characteristic 
feature of COPD is the presence of acute exacerbations, 
which are typically associated with increased inflamma-
tion. Important causes of exacerbations include infec-
tions (bacterial, viral and combined viral/bacteria) and 
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environmental factors. Exacerbations of COPD are 
strongly associated with mortality, hospitalization and 
decline in functional status [7].
Smoking is the principal risk factor for COPD but bio-
mass exposure particularly from cooking in poorly ven-
tilated homes, is being increasingly recognized as being 
important [8]. Patients typically develop clinical symp-
toms many years after the initiation of smoking and this 
condition is generally diagnosed over the age of 50 years 
with a peak incidence at approximately 70 years [9].
Once established the inflammatory process in COPD 
is persistent despite smoking cessation and progresses 
over time [10]. It has been shown by Hogg et  al. that 
after smoking cessation, there is progressive small air-
flow obstruction in patients with COPD, a number of 
years after smoking cessation. This small airflow obstruc-
tion was due to (1) the accumulation of inflammatory 
mucous exudates in the lumen and (2) increase in the 
tissue volume of the bronchial wall. The increase in the 
tissue volume of the bronchial wall was characterized by 
infiltration of the wall by both innate (macrophages/neu-
trophils) and adaptive inflammatory immune cells (CD4, 
CD8 and B lymphocytes) that formed lymphoid follicles.
The factors that drive inflammation in COPD after 
smoking cessation have not been clearly established 
although autoimmunity, embedded particles/heavy met-
als from smoking and chronic bacterial infection have all 
been proposed to have a role [11]. The most commonly 
associated factor with lung inflammation in COPD is 
autoimmunity. Lee et  al. showed that emphysema is 
an autoimmune disease characterized by the presence 
of antielastin antibody and T-helper type 1 [T(H)1] 
responses, which correlates with emphysema severity 
[12]. Using both in vivo animal models and human lung 
epithelial cells Ghio et al. showed that cigarette smoking 
increased lung iron and ferritin levels [13]. A recent study 
described increased levels of cadmium and manganese 
in the lungs of patients with advanced COPD [14]. New 
work has highlighted the importance of the microbiome 
in lung disease [15–17]. The most common bacterium 
isolated from the lungs of patients with COPD is non-
typeable Haemophilus influenzae (NTHi). NTHi induces 
changes of COPD in an animal model [18] and new 
strains are also associated with exacerbations of COPD 
[19]. This bacterium has also been shown to activate lung 
T cells [20] and cause the expression of reactive oxygen 
species and proteases in patients with COPD [21].
Inflammatory cell types prominent in COPD
There are a variety of cell-types that contribute to inflam-
mation in COPD, of which the most important are the 
macrophages, the neutrophils and the lymphocytes [11, 
22, 23].
Macrophages
Macrophages have a key role in the pathogenesis of 
COPD and are found in markedly increased numbers in 
both the airways and lung parenchyma. There is a direct 
correlation between the presence of parenchymal mac-
rophages and emphysema [24]. Smoking activates mac-
rophages to produce a variety of inflammatory mediators 
including chemokines, reactive oxygen species (ROS) 
and proteases. Patients with COPD have macrophages 
that are more inflammatory than in subjects who smoke 
but who do not have COPD [25]. Macrophages are also 
heterogeneous and have different functional characteris-
tics in different organs. These cells also display polarity 
in their function with M1 cells being more inflammatory 
and M2 cells being associated with a healing immune 
responses and fibrosis [26, 27]. Studies have reported that 
macrophages from patients with COPD have decreased 
phagocytosis of common bacteria such as H. influenzae 
and Streptococcus pneumoniae and this could be a con-
tributing factor to chronic airway colonization [28–30].
Neutrophils
Neutrophils are generally more inflammatory than mac-
rophages and are most prominent in acute exacerbations 
in the lung airways [23, 31]. Smoking increases the pres-
ence and activation of neutrophils in the respiratory tract 
[32]. Neutrophils are a potent source of proteases, par-
ticularly neutrophil elastase and reactive oxygen species 
(ROS).
Lymphocytes
As COPD progresses a distinctive feature is the develop-
ment of lymphoid follicles in the small airway walls [10]. 
These lymphoid follicles are composed of T and B cells 
[33]. T cells are also found in the lung parenchyma and 
airways and studies have reported a relatively increased 
proportion of CD8+ cells to CD4+ cells. Studies have 
most commonly reported that these cells display a Th1/
Tc1 polarity [20, 23, 32] although there is some variabil-
ity in the literature whilst Th17 responses (defined by TH 
cells that produce the cytokine IL-17) have also been 
reported [34]. Roos et  al. have recently shown that IL-
17A is elevated in end-stage COPD and this contributes 
to cigarette smoke-induced lymphoid neogenesis [35]. 
Samples in this study were taken from human lung tis-
sue and cigarette smoke exposed mice. Cigarette smoke 
exposure has been shown to upregulate IL-17 expression 
in human lung tissue [36] and in mice [37].
Other inflammatory cell types
Other inflammatory cell types involved in COPD include 
eosinophils, dendritic cells and mast cells. The pres-
ence of eosinophils in COPD may be associated with 
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co-existent asthma and levels of eosinophil basic proteins 
have been found to be elevated as well [38]. Increased 
numbers of activated pulmonary dendritic cells are found 
in patients with COPD and are a marker of disease sever-
ity. Mast cells are widely distributed in the airways and 
have a well-established role in asthma inflammation [39]. 
In COPD mast cells upregulate markers of inflammation 
[40] and the distribution of these cells in the lung differs 
between centriacinar and panlobular emphysema [41].
Structural lung cells and their contribution to lung 
inflammation
Epithelial cells
The epithelial cells also have an important role in medi-
ating inflammation in COPD. These cells are activated 
by inhaled toxins, such as cigarette smoke and biomass 
smoke as well as by microorganisms [42]. This results 
in the production of a variety of inflammatory media-
tors including cytokine, chemokines and ROS. Smoking 
induces expression of the mediator CXCL14 by human 
epithelial cells and this is correlated with the develop-
ment of lung cancer [43].
Inflammatory mediators
There is a complex network of inflammatory media-
tors produced by inflammatory and structural cells in 
the lung including chemokines, growth factors and lipid 
mediators. The factors most clearly associated with path-
ogenic inflammation in COPD are cytokines, reactive 
oxygen species and proteases [11, 23]. The production of 
inflammatory mediators is triggered by the activation of 
Toll like receptors (TLRs) and lymphocyte antigen recep-
tors which; through intracellular signaling pathways such 
as nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κβ) and signal transducers and activators of 
transcription (STATs) leads to mediator release.
Cytokines
Cytokines in the lung are principally produced by mac-
rophages and T cells. There is a range in the outcomes 
reported between different studies as a variety of differ-
ent techniques have been used and studies have reported 
baseline levels and responses to stimulation. Important 
mediators produced by macrophages and neutrophils 
include tumor necrosis factor alpha (TNF-α), interleu-
kin (IL)-1, IL-6 and IL-8. These cytokines are markedly 
proinflammatory in COPD [11, 23]. Consistent with Th1 
responses, levels of interferon gamma (IFN-γ) and TNF-α 
are elevated in COPD particularly in the baseline state. 
These two cytokines are associated with active inflam-
mation. Interestingly both IFN-γ and IL-13 (Th2) models 
have been associated with the development of emphy-
sema in mice [44]. Recent publications have highlighted 
that there are elevated levels of IL-17 in patients with 
COPD [34].
Reactive oxygen species
The excessive production of reactive oxygen species dam-
ages the lung tissue and results in oxidative stress, which 
is a primary pathogenic process in COPD. The phago-
cytes (neutrophils and macrophages) and epithelial cells 
all produce ROS and this process is enhanced in patients 
with COPD. Antioxidants such as superoxide dismutase 
(SOD), glutathione and catalase are produced to coun-
teract the effect of ROS and are regulated by the nuclear 
erythroid-2-related factor-2 (Nrf2) [45]. In patients with 
COPD there is deficient activation of Nrf2. ROS has a 
wide range of pro-inflammatory effects [46]. ROS also 
activates inflammatory transcription pathways [47]. Oxi-
dative stress inhibits the activity of sirtuin-1 that is an 
important in tissue repair [48], and activates growth fac-
tors and damages DNA. Oxidative stress also contributes 
to accelerated aging of the lung in COPD [49].
Proteases
Proteases are produced by neutrophils and macrophages. 
These include neutrophil elastase and matrix metal-
loproteinases (MMP) 9 and 12. The proteases are prin-
cipal factors driving the development of emphysema 
[50]. Their effect is opposed by anti-proteases such as 
α-1 antitrypsin. Deficiency of α-1 antitrypsin may result 
in the severe and early onset of emphysema. They also 
are involved with the activation of neutrophil-mediated 
inflammation [51] and increased arterial stiffness.
The binding of surface receptors (e.g. toll like recep-
tors and antigen receptors) on immune cells by a diverse 
range of stimuli (including cytokines, ROS, oxidized 
low density lipoprotein and bacterial antigens) activates 
intracellular signaling pathways that drive the inflam-
matory response. Two important intracellular signaling 
pathways relevant to COPD are NF-κβ and STATs.
Systemic inflammatory response
Chronic obstructive pulmonary disease is associated with 
a prominent systemic immune response that is more pro-
nounced with advanced disease and in exacerbations. 
Systemic inflammation has been defined as the pres-
ence of inflammatory/immune response mediators that 
are present in the peripheral blood with levels that are 
elevated in COPD when compared to smoking controls 
(without COPD). Systemic inflammation as measured by 
the biomarkers; C-reactive protein (CRP), leukocytes and 
fibrinogen is associated with a two to four-fold increased 
risk of comorbidities including cardiovascular disease 
and lung cancer [52]. Another study used 6 inflamma-
tory markers (CRP, IL-6, IL-8, TNF-α, fibrinogen and 
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leukocytes) found elevation of at least one component 
in 70% of patients and persistent inflammation in 16%. 
Inflammatory biomarkers are also associated with car-
diovascular disease and COPD and will be discussed in 
more detail in the individual sections below.
There have been a large number of studies that have 
described systemic inflammation occurring in COPD 
but the definition of what this entity is has often not been 
clear [53]. It is not clear if the systemic inflammatory 
response represents a spillover of mediators from the 
lung or is primarily a separate systemic component to the 
disease [54, 55]. This issue is of most relevance to compli-
cations such as osteoporosis, cerebrovascular disease and 
muscle wasting, rather than lung cancer and coronary 
artery disease with their intimate proximity to the lung.
Cardiovascular disease and COPD
The risk of cardiovascular disease is significantly 
increased in patients with COPD. A diagnosis of COPD 
increases the risk of cardiovascular disease by an odds 
ratio (OR) of 2.7 [56]. COPD also increases the risk of 
mortality from CVD disease (OR of 1.68) [57]. There is 
marked overlap in risk factors in the two conditions par-
ticularly, smoking, older age and male sex. However lung 
inflammation is an important independent risk factor for 
cardiovascular disease and this section will discuss spe-
cific mechanisms involved in this process [58].
Inflammation has been increasingly recognized to 
have a role in atherosclerosis particularly in the context 
of coronary artery disease. Blood borne immune and 
inflammatory cells are an important component of ath-
eroma. Macrophages and T cells infiltrate atheroma with 
the production of inflammatory cytokines. Activated 
immune cells (macrophages and T cells) are abundant at 
sites of plaque rupture and appear to play an important 
role in acute thrombosis and coronary syndrome [59, 
60]. Important cytokines in this process include TNF-α, 
IFN- γ, IL-1 and IL-6.
Coronary artery disease
In patients with COPD there is a significantly higher risk 
of coronary artery disease (OR 2.0), angina (OR 2.1) and 
myocardial infarction (OR 2.2) [56]. The degree of air-
flow obstruction is associated with increased mortality 
from ischemic heart disease [61]; for each drop of 10% in 
forced expiratory volume in 1  s (FEV1), CVD mortality 
increases by 28% and the incidence of non-fatal coronary 
events increases by 20% [62]. The presence of coronary 
artery disease is often not recognized. A study of inpa-
tients with COPD found evidence of myocardial infarc-
tion on electrocardiogram in 27%, but in most subjects 
(70%) this was not documented in the clinical history 
[63].
The systemic inflammatory response may cause 
endothelial injury and vascular dysfunction, although the 
exact mechanisms of how this occurs remain to be deter-
mined. There are number of mechanisms which could 
contribute to this effect. Inflammatory cytokines pro-
duced by T cells and macrophages including IL-1, IL-6 
and TNF-α all affect endothelial function [64]. There is 
increased endothelial permeability in COPD in response 
to mediators. The oxidative stress affects blood vessels 
including effects such as vasoconstriction and increased 
uptake of oxidated LDL cholesterol. There is inhibition of 
nitric oxide resulting in a vasoconstrictive state.
Patel et  al. measured (1) arterial stiffness (as assessed 
by aortic wave velocity) and (2), cardiac biomarkers 
[troponin and N-terminal pro-brain natriuretic peptide 
(BNP)] and their relationship to COPD exacerbations 
and airway infection/inflammation [65]. They found that 
frequent COPD exacerbators had greater arterial stiffness 
than infrequent exacerbators and this was significantly 
associated with the inflammatory state as defined by the 
sputum levels of IL-6. In addition exacerbations of COPD 
were associated with significant rises in troponin and 
BNP, and the rises in these cardiac biomarkers correlated 
with higher serum CRP and sputum IL-8.
Thomsen et  al. measured the relationship between 
elevated levels of three inflammatory biomarkers (CRP, 
fibrinogen, and leukocyte count) and comorbidities in 
a cohort of 8,656 patients with COPD [66]. They found 
that the risk of ischemic heart disease was increased by 
a factor of 2.19 in subjects who had all three biomark-
ers elevated (when compared to subjects who had all 
biomarkers in the normal range). Corresponding hazard 
ratios were 2.32 for myocardial infarction and 2.63 for 
heart failure.
The inflammation in COPD increases coagulopathy. 
Patients with this condition have elevated basal levels of 
Factor VIIa, tissue factor and thrombin-antithrombin 
complexes [67]. Plasma fibrin clots from patients with 
COPD are denser and more resistant to lysis and this 
effect can be inhibited by the use of simvastatin [68]. In 
addition hypoxaemia in patients with COPD, elevates 
levels of IL-6, prothrombin activation fragments and 
thrombin-antithrombin complex [69].
In unstable angina neutrophilic inflammation is present 
in the coronary arteries, suggesting that acute inflamma-
tion has a role in this process [58, 70]. It has recently been 
proposed that acute exacerbations of COPD with their 
associated neutrophil influx may be triggers for acute 
coronary events [71]. This proposal is supported by stud-
ies that have demonstrated that both acute respiratory 
infection and exacerbations of COPD are associated with 
a markedly increased incidence of acute coronary events 
[72, 73].
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Troponin is a marker of myocardial stress/ischemia. 
Patients with COPD have elevated troponin levels, both 
at baseline and particularly in context of acute exacerba-
tions [74, 75]. The elevation of troponin in the context of 
AECOPD is associated with the presence of neutrophilia 
consistent with an inflammatory component [76].
Pulmonary artery disease
Changes in the pulmonary arteries occur in COPD 
and may result in pulmonary hypertension and right 
heart hypertrophy and this is an important factor in the 
increased risk of mortality. There are a variety of factors 
that contribute to this process, of which the two most 
important appear to be endothelial dysfunction [77] 
and coagulopathy. Hypoxaemia is recognized to have an 
important role in the development of pulmonary artery 
disease [78]. The relation between pulmonary artery dis-
ease and inflammation is less well defined than the previ-
ously discussed cardiac comorbidities. There is increased 
infiltration of pulmonary arteries by CD8+ T cells, which 
correlates with pulmonary hypertension. Other inflam-
matory markers associated with pulmonary artery dis-
ease in COPD include CRP, IL-6, MCP-1, TNF-α and 
phospholipid ceramide [79].
Venous thromboembolism
There is an increased risk of venous thromboembolism 
(VTE) in patients with COPD. This is an area that has 
not been comprehensively studied, and there is a range 
in findings. In the context of acute exacerbations VTE is 
present in 3–29% of patients [80, 81]. Occult pulmonary 
embolism (PE) may have a role in precipitating AECOPD 
as well. There is an increased incidence of all the key risk 
factors for VTE in COPD (coagulopathy, endothelial dys-
function and venous stasis). The higher risk of VTE in 
exacerbations suggests that an inflammatory component 
may be relevant.
Cerebrovascular disease
There appears to be a moderately increased risk of cer-
ebrovascular disease in COPD, both in stable state and 
with acute exacerbations [82]. The risk is inversely pro-
portional to the FEV1 and is more prominent in younger 
patients [83]. Systemic inflammation increases the risk 
of acute ischemic stroke [84]. Studies have reported 
worse neurological deficits in association with preced-
ing infection in human studies and in animal models 
[85, 86]. Similar to coronary artery disease, activated 
macrophages and T cells are prominent in plaques in the 
cerebral circulation and secrete proteases such as MMPs 
which destabilize the plaque and increase the risk of 
rupture.
Lung cancer and COPD
Lung cancer (defined as primary bronchogenic lung 
cancer) is the leading cause of cancer death worldwide, 
accounting for 1.59 million deaths in 2012 [87]. Smok-
ing is the primary risk factor associated with lung can-
cer. However only 20–25% of smokers develop COPD 
and the presence of COPD is associated with a two to six 
times risk for the development of lung cancer compared 
to smokers without COPD [88, 89]. In addition COPD is 
associated with lung cancer in never smokers. The mor-
tality of lung cancer is also correlated with the co-exist-
ence of COPD. The risk is highest for squamous cell lung 
carcinomas [89]. Airflow obstruction and the presence 
of emphysema on CT scanning are also independent risk 
factors for the development of lung cancer [89, 90].
The pathways that lead to the development of lung 
cancer are complex and only partially understood. In 
addition to smoking, chromosomal translocation and 
epigenetic modifications have important roles in the 
development of lung cancer [91–94]. Finally the pri-
mary pathogenesis of COPD is characterized by lung 
inflammation and there is increasing data about the role 
of inflammation in the development of cancer [95]. In a 
large prospective study an elevated CRP level increased 
the risk of lung cancer [96]. The use of inhaled corticos-
teroids have been associated the decreased risk of lung 
cancer although this study was retrospective [97]. The 
large variety of inflammatory mediators present in the 
lungs of COPD patients promotes the development of 
epithelial-to-mesenchymal transition (EMT) and lung 
cancer [98]. In animal models inflammation is a crucial 
factor in the development of lung cancer and depletion 
of macrophages and B cells is protective [32]. There are 
a number of inflammatory processes that can potentially 
contribute to the development of lung cancer and these 
will be discussed in more detail.
Inflammatory cell types and lung cancer
Lung cancer is associated with an inflammatory envi-
ronment with localized leukocyte infiltration and the 
most well characterized cellular responses have been of 
macrophages and T cells. Recent literature has also high-
lighted the role of other cell types such as the neutrophils 
and dendritic cells.
Macrophages
Monocytes migrate into tumors where they differentiate 
into macrophages under the influence of factors includ-
ing monocyte-chemotactic protein (MCP-1), vascular 
endothelial growth factor (VEGF) and hypoxia. The dif-
ferentiated macrophages in the tumor environment are 
designated as tumor associated macrophages (TAMs) 
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[99]. These TAMs can develop into polarized M1 or 
M2 phenotypes. The M1 phenotype TAMs, are typi-
cally associated with antimicrobial function and tumor 
cell killing/inhibition. In contrast the M2 TAMs have a 
different cytokine functional profile and are associated 
with tissue remodeling/repair and angiogenesis; they are 
also tumor promoting [100]. In the early phase of tumor 
development the M-1 phenotype predominates whilst 
as tumor development progresses the M-2 phenotype 
becomes more dominant particularly in hypoxic tumor 
regions [101]. These hypoxic-driven TAMs express pro-
angiogenic factors such as vascular endothelial growth 
factor (VEGF) and MMP9 as well as lymphangiogenic 
factors. The M1 and M2 responses are mutually antago-
nistic. Differentiating between M1 and M2 macrophages 
may be challenging and these cells demonstrate signifi-
cant plasticity [102]. Published studies have been done 
predominantly in subjects with non small cell lung cancer 
(NSCLC).
Neutrophils
Neutrophils have been less intensively studied than 
macrophages in lung cancer. Several studies described 
the presence of tumor-associated neutrophils (TAN) in 
murine models. Eruslanov et al. have recently described 
that TANs have a prominent role in early-stage human 
lung cancer [103] and constituted between 5 and 25% of 
cells in these tumors. The TANs in this study displayed 
an activated phenotype with a distinct repertoire of 
chemokine receptors and proinflammatory factor pro-
duction including MCP-1, IL-8, MIP1α and IL-6. This 
study concentrated on early stages of lung cancer and 
found that the TANs were associated with stimulation 
of T cell responses and could represent a type 1 TAN. 
Similar to M1/M2 polarization a paradigm of N1 (antitu-
mor) and N2 (protumor) responses has been proposed in 
murine models of lung cancer [104].
Lymphocytes
Lymphocyte responses are important in cancer, in par-
ticular cytotoxic T cell responses have a key role in con-
trolling/eliminating neoplastic cells. Advanced COPD 
is characterized by prominent infiltration of the lung by 
lymphocytes, particularly CD8+ cells [50]. The nature 
of the T cell responses has still not been well defined 
in COPD although the bulk of the published litera-
ture describes a Th1/Tc1 predominant response. Such a 
response would be expected to be proinflammatory with 
enhanced antitumor M1 responses. In contrast a study of 
responses of lung tissue T cells to stimulation by the bac-
terium H. influenzae found that subjects with COPD had 
a Th2/Tc2 predominant response [20]. However this area 
is still not well defined. Th17 cells appear to be relevant in 
the development of lung cancer and will be discussed in 
more detail in the subsequent section [105].
Other cell types also have a potential role in COPD and 
lung cancer, including natural (NK) cells, mast cells, den-
dritic cells and eosinophils [32, 106]. Defective NK cell 
responses may be important in the development of meta-
static disease. There is conflicting published literature 
about the role of dendritic cells in lung cancer.
Inflammatory mediators and lung cancer
There are a large number of inflammatory mediators pro-
duced in COPD, which are relevant for the development 
of lung cancer but their interactions are complex and not 
fully understood in this context.
Cytokines
Three prominent cytokines produced in the COPD are 
TNF-α, IL-1, and IL-6, and these all also have important 
roles in lung cancer. Tumor necrosis factor-α, which is 
predominantly secreted by T cells and macrophages, pro-
motes carcinogenesis by inducing cell transformation/
proliferation and tumor growth [107]. Malignant cells 
may also produce TNF-α, which may enhance tumor 
development. Interleukin-1 is produced by macrophages 
and tumor cells and is associated with enhanced tumo-
rigenesis and the production of mediators such as ROS 
and proteases [108]. IL-1 and TNF-α are key mediators 
involved in the initiation of the inflammatory response. 
Interleukin 6 is secreted by macrophages and also by 
T cells (in the context of chronic inflammation) and 
has been clearly implicated both in the pathogenesis of 
COPD and in lung cancer. Ochoa et al. ablated IL-6 in a 
mouse cancer model and found that this markedly inhib-
ited both the development of COPD-like lung inflamma-
tion and lung cancer [109]. IL-6 levels are elevated in lung 
cancer patients in cells lines with endothelial growth fac-
tor receptor (EGFR) mutations which results in STAT3 
elevation [110].
Cytokines such as TNF-α, IL-1 and IL-6 induce tran-
scription factors that drive inflammation including NF-κβ 
and STAT3. Both of these transcription factors/pathways 
are upregulated in COPD and lung cancer. There are 
a number of links between NF-κβ and carcinogenesis 
including upregulation of inflammation, cell transforma-
tion, proliferation and migration, and enhancement of 
the production of MMPs and angiogenic factors [111]. 
STAT3 is present in the cytoplasm and are activated by 
several factors particularly IL-6. STAT3 may upregulate 
expression of NF-κβ and has increased expression in lung 
cancer. The NF-κβ and STAT3 pathways facilitate the 
development of EMT [98, 112].
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Proteases
Proteases such as neutrophil elastase and MMP9 and 
MMP12 have a key role in the pathogenesis of COPD. 
The MMPs have also been strongly implicated in the 
pathogenesis of lung cancer and have a variety of effects 
including the promotion of angiogenesis. The degrada-
tion of components of the extracellular matrix by pro-
teases activates growth factors that stimulate endothelial 
cells to multiply and produce new capillaries, driving 
angiogenesis [113, 114]. Proteases may also facilitate 
metastasis by breaking down the lung matrix [115].
Reactive oxygen species
Oxidative stress with the excess production of reac-
tive oxygen species is one the key pathogenic processes 
in COPD. Oxidative stress also has a major role in the 
development of lung cancer. ROS damages DNA and 
promotes its mutation by inhibiting the function of DNA 
repair genes and increases the expression of DNA meth-
yltransferases [116]. As discussed previously the Nrf2 
transcription factor may be downregulated in COPD 
with potentially enhanced damage from ROS.
Systemic inflammatory markers
Systemic inflammatory markers are also associated 
with an increased risk of lung cancer and there have 
been a number of publications in this area particularly 
in relation to CRP. Thomsen et al. found that the eleva-
tion of three inflammatory markers (CRP, fibrinogen 
and leukocyte count) had a hazard ratio of 4.0 for the 
development of lung cancer [66]. A study assessed the 
correlation between circulating inflammatory markers 
and the prospective development of lung cancer [117]. 
Significant associations were found between the risk of 
lung cancer and levels of both CRP and serum amyloid 
A protein. A meta-analysis of the association between 
CRP, IL-6 and lung cancer; found that CRP was associ-
ated with an increased risk of lung cancer (particularly in 
men) but there was no association with Il-6 levels [118].
Table 1 summarizes the key inflammatory cells/media-
tors and their effects in COPD, CVD and lung cancer.
Therapeutic strategies against COPD to reduce 
CVD and lung cancer
There has been extensive interest over many years in 
agents that could be used to reduce inflammation in 
COPD. The reduction of inflammation in COPD may 
reduce the increased risk of CVD and lung cancer that 
occurs in this context, although the clinical trials that 
have addressed this issue are very limited.
Pharmaceutical therapy for the treatment of inflamma-
tory process in COPD is relatively ineffective [119]. The 
major therapy that has been used is corticosteroids both 
in systemic form and particularly as inhalational therapy. 
Whilst inhaled corticosteroids (ICS) reduce frequency 
of exacerbations in COPD most patients are resistant to 
these medications for the control of chronic inflamma-
tion. However a retrospective study reported that the use 
of ICS reduced lung cancer [97]. Corticosteroids have 
very broad immunosuppressive effects and particularly in 
long-term use, major side effects. Recent work has con-
centrated on developing more targeted approaches to 
immune suppression in COPD. In this section the work 
that is most relevant to the comorbidities of CVD and 
Table 1 Common inflammatory cells/mediators in COPD, CVD and lung cancer
COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, M1/M2 types one and two macrophage subsets, TAM tumor-associated macrophages, IL 
interleukin, TNF-α tumor necrosis factor alpha, STAT signal transducers and activators of transcription, ROS reactive oxygen species.




Primary producer of inflammatory media-
tors in COPD, M1/M2 function
Major producer of inflammatory mediators, 
important in plaque rupture
Primary inflammatory cell in lung cancer, 
TAM1/TAM2 function
 Neutrophil Key role in exacerbations, produces IL-8, 
elastase
May have role in precipitating acute coro-
nary events
Proinflammatory, produces IL-8, elastase
 T cell Key driver of inflammation in advanced 
disease, major source of cytokines
Infiltration of plaques CD8+ cells important in killing tumor cells, 
secretor of cytokines
Inflammatory mediator
 TNF-α Marked proinflammatory effect Proinflammatory, affects endothelial func-
tion
Proinflammatory, promotes carcinogenesis
 IL-1 Proinflammatory effect Proinflammatory, affects endothelial func-
tion
Enhances tumorigenesis and ROS/proteases
 IL-6 Proinflammatory effect Proinflammatory affects endothelial func-
tion
Enhances tumorigenesis (STAT3), inflam-
mation
 ROS Damages lung tissue Proinflammatory, damages endothelium Damages DNA, enhances tumorigenesis
 Proteases Causes emphysema Role in plaque instability Promote tumor angiogenesis/metastasis
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lung cancer will be summarized. Potential key targets are 
highlighted in Fig. 1.
Therapies to target potential causes of lung inflammation
The most important therapeutic intervention in the 
treatment of COPD is the cessation of smoking. However 
inflammation in COPD persists, and in more advanced 
disease progresses despite smoking cessation. This per-
sistence of the inflammatory process after smoking ces-
sation is not well understood but represents a potential 
major therapeutic target. There have been studies dem-
onstrating that autoimmunity may have a role in the 
pathogenesis of COPD but standard anti-inflammatory 
therapies have so far been relatively ineffective. Bacterial 
infection is very prevalent in COPD and antibiotics have 
been used as standard therapy for exacerbations. The role 
of bacteria in the chronic inflammatory process of COPD 
is still not well defined. There have been a number of 
recent trials of macrolides as maintenance therapy, which 
have demonstrated a marked reduction in the frequency 
of exacerbations of COPD; whether this is antimicrobial 
or anti-inflammatory effect is not clear [120]. A recent 
trial of anti-IL-17 therapy found there was a reduction in 
lung cancer in a mouse model and this also occurred with 
H. influenzae infection [105].
Intracellular signaling pathways
The primary stimuli act on the cell surface receptors (e.g. 
toll like receptors and lymphocyte receptors) to activate 
intracellular signaling pathways to drive the produc-
tion of inflammatory mediators. These signaling path-
ways are complex but tyrosine kinases are major drivers 
of this cascade and activate downstream pathways such 
as NF-κβ and STAT3. Tyrosine kinase inhibitors include 
phosphodiesterase inhibitors that act to inhibit intra-
cellular cyclic AMP and GMP, with a variety of effects 
including inhibition of inflammatory mediators. Theo-
phylline is a phosphodiesterase inhibitor that has been 
used for many years but only has mild therapeutic effects 
with a high incidence of toxicity. The phosphodiester-
ase inhibitor roflumilast inhibits neutrophil recruitment 
and activation, T cell activation and monocyte chemot-
axis and has clinical benefits including reducing exac-
erbations and improving lung function although it did 
not alter levels of CRP [121–123]. Roflumilast does have 
a high incidence of side effects though. Kinase inhibi-
tors affect important inflammatory signaling pathways 
including NF-κβ and STAT3 production and the produc-
tion of inflammatory mediators such as IL-1, TNF-α and 
MMP9. There are number of kinase inhibitors that have 
been developed particularly against p38 mitogen-acti-
vated protein kinase and phosphoinositide 3-kinase but 
these compounds are currently mainly being tested in the 
pre-clinical setting.
Cytokine production
The inflammatory cytokines, TNF-α, IL-1 and IL-6 are 
elevated in COPD, CVD, and lung cancer and are poten-
tial therapeutic targets particularly in the context of 
acute exacerbations. There are several strategies that can 
be used to inhibit the effects of IL-1 and these include 
receptor antagonists, blocking monoclonal antibodies 
and an IL-1 trap. These approaches have been demon-
strated useful effects in other inflammatory diseases 
such as gout [124]. Currenlty an IL-1 blocking antibody 
(canakinumab) is being investigated for the treatment 
of several conditions including COPD [125]. TNF-α 
has a major role in driving inflammation and targeted 
therapies in rheumatoid arthritis with blocking anti-
body therapy such as infliximab have been highly effec-
tive. Unfortunately infliximab in a trial in patients with 
COPD showed no clinical improvement after 6 months 
and was associated with major side effects [126]. Anti 
IL-6 antibodies (tocilizumab) have benefits in patients 
Fig. 1 Potential targets for anti-inflammatory therapy The inflam-
matory process in COPD is associated with cardiovascular disease 
and lung cancer and is a potential therapeutic target to reduce these 
comorbidities. In additional to broad spectrum therapies such as 
corticosteroids specific anitinflammatory therapies could be directed 
towards a the primary factors driving inflammation in COPD, b intra-
cellular signaling pathways including NF-κβ and STAT3 e.g. by tyros-
ine kinase inhibitors, c inhibition of specific inflammatory cytokines 
such as tumor necrosis factor alpha (TNF-α) and interleukins (IL) 1 
and 6 and the generation of d reactive oxygen species (ROS) and e 
proteases such as neutrophil elastase (NE) and matrix metalloprotein-
ases 9 and 12 (MMP9/12).
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with refractory rheumatoid arthritis but have not been 
tried in patients with COPD [127]. Interleukin 8 is a key 
chemotactic factor for neutrophils and monocytes but a 
clinical trial of a blocking antibody failed to show ben-
efit [128]. An issue for the treatment of COPD-driven 
inflammation and its associated comorbidities is that 
there is elevation of many inflammatory mediators and 
the targeting of one specific cytokine has so far proved 
ineffective.
Protease and reactive oxygen species production
Two broad inflammatory processes relevant to COPD 
are protease imbalance and oxidative stress. There are 
specific anti-proteases available. A specific inhibitor of 
neutrophil elastase is effective in an animal model but 
was not found to be beneficial in a clinical trail [129]. The 
MMPs may be more important in the chronic inflamma-
tory process than neutrophil elastase, but a dual MMP9/
MMP12 inhibitor developed in animals has not yet been 
used in clinical trials at this stage [130]. Oxidative stress 
has been a therapeutic target in a variety of conditions 
but has generally been relatively resistant. N-acetyl-
cysteine is a well-established therapy but its anti-oxidant 
effect has generally been disappointing. A number of new 
and more potent anti-oxidants have been developed but 
in limited animal and clinical trials have generally not 
been effective.
Corticosteroids
Corticosteroids remain the cornerstone of asthma treat-
ment but are generally relatively ineffective in COPD. 
There has been renewed interest in the identification of 
factors that could reverse this corticosteroid resistance. 
A potential mechanism is reduced histone deacetylase 
2-mediated deacetylation of the glucocorticoid recep-
tor expression with associated oxidative stress [131]. The 
addition of other agents with corticosteroids such as low-
dose theophylline and tricyclic antidepressants may be 
potentially beneficial in this circumstance [132, 133].
Statins
Statins are a potentially promising therapy in COPD. In 
addition to their lipid lowering properties they reduce 
the stability of lipid raft formation with inhibition of 
signaling and cytokine, chemokine and adhesion mole-
cule expression. This inhibits systemic inflammation with 
decreased CRP. Two systematic reviews of the observa-
tional studies published have reported beneficial effects 
of statins in COPD, including decreased mortality and 
improved lung function [134, 135]. Statins may also have 
a role in improving lung cancer outcomes. A large retro-
spective study reported that the used of statins reduced 
lung cancer mortality and metastatic disease [136].
Conclusions and future directions
Chronic obstructive pulmonary disease is characterized 
by lung inflammation that persists after smoking cessa-
tion. This inflammation is heterogeneous but the key cell 
types involved are macrophages, neutrophils and T cells, 
The dominant inflammatory mediators include TNF-α, 
IL-1, IL-6, reactive oxygen species and proteases. COPD 
is also associated with systemic inflammation and there 
is a markedly increased risk of cardiovascular disease 
(particularly coronary artery disease) and lung cancer in 
patients with COPD. This inflammation is an independ-
ent risk factor (additional to smoking, male sex etc.) for 
these comorbidities. There is strong associative evidence 
that the inflammatory cells/mediators in COPD are also 
relevant to the development of CVD and lung cancer. 
There are a large number of potential inhibitors of inflam-
mation in COPD that may well have beneficial effects for 
these comorbidities. Particularly in lung cancer, which 
has a 5-year survival of less than 20%, the development of 
new and more effective therapies is urgently needed.
There are some priority areas in the study of COPD 
and its associated CVD and lung cancer morbidities (see 
Table 2). Firstly, there needs to be more definitive human 
clinical studies to establish the link between COPD and 
CVD/lung cancer, particularly large prospective tri-
als. The mechanisms that link COPD with its comor-
bidities have not been adequately defined due to lack of 
established experimental/animal models. Finally there 
is a need for the development of targeted inhibitors of 
inflammation, which prevent harmful immune responses 
but do not have major side effects. Perhaps the most 
potentially useful area to target is to identify the specific 
factors that drive inflammation in COPD after smoking 
cessation.
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Table 2 Priority areas
More definitive, prospective, human clinical studies to define the links 
between the inflammatory process of COPD and cardiovascular dis-
ease/lung cancer
The development of experimental/animal models to define how the 
inflammation in COPD increases the risk of cardiovascular disease/lung 
cancer
The development of targeted antiinflammatory therapies in COPD to 
reduce the associated cardiovascular disease/lung cancer
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